Skip to content
Head to head

TG Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TGTX · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

TGTX +106.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals trades cheapest on trailing earnings; Vertex Pharmaceuticals earns the most per share.
TGTXVRTX
Snapshot
Sector--Biotechnology
Last price63.34515.02
Change today-2.37%-1.08%
1-year return+108.0%+22.0%
Market cap$9.57B$130.58B
52-week range26.76 – 68.03412.27 – 568.67
Valuation
P/E (TTM)94.5433.14
P/E percentile, own 5-yr range88th99th
P/B16.736.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.7715.32
Net profit (TTM)$418.68M$3.88B
Revenue (TTM)$897.76M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+60.7%+11.8%
Gross margin82.7%85.5%
Operating margin21.5%33.1%
Net margin11.8%30.7%
Free cash flow (TTM)$85.56M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership88.7%96.8%
Insider activity (12mo)21 buy / 26 sell28 buy / 22 sell
Short interest (% of float)18.8%1.9%
Analyst consensus83% buy / 17% sell (6)95% buy / 5% hold (21)
Analyst price target$76 (+21%)$624 (+21%)
StockVane view
StockVane Quant RatingC (98)C (68)
Company
Employees3996,400
Founded19931989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.